Article Data

  • Views 414
  • Dowloads 102

Original Research

Open Access

Concomitant chemoradiation treatment in selected Stage I endometrioid endometrial cancers

  • D. Rossetti1
  • S.G. Vitale2
  • F.A. Gulino3
  • P. Cignini4
  • A.M.C. Rapisarda2
  • A. Biondi3
  • L. Frigerio1

1Department of Obstetrics and Gynecology, "Papa Giovanni XXIII" Hospital, Bergamo, Italy

2Department of Medical Surgical Specialties, Gynaecology and Obstetrics Section, University of Catania, Catania, Italy

3Department of Surgery, University of Catania, Catania, Italy

4Department of Gynecologic Ultrasound Imaging, ALTAMEDICA Fetal Maternal Medical Centre, Rome, Italy

DOI: 10.12892/ejgo3125.2016 Vol.37,Issue 5,October 2016 pp.657-661

Published: 10 October 2016

*Corresponding Author(s): S.G. Vitale E-mail: vitalesalvatore@hotmail.com

Abstract

Purpose of investigation: To evaluate chemotherapy with concomitant radiotherapy (RT) in "high risk" endometrial cancer (EC) patients. Furthermore to develop a new algorithm for management and treatment. Materials and Methods: The study included 182 Stage I endometrioid EC patients who underwent definitive surgery after a first treatment. Stage, grade, ploidy DNA index, lymphovascular space involvement (LVSI), tumor diameter (TD), and p53 were considered to identify "high-risk" patients. Twenty-seven women received adjuvant concomitant chemoradiation (CR). Toxicity related to the CR treatment, disease free interval (DFI), and status of the patients were considered. Results: Twenty-seven patients according to the present algorithm treatment were considered at "high risk". Median follow up was 43 months (range 16-68). Twenty-five (92%) patients completed CR treatment. Overall, grade 3/4 hematological toxicity was 18% while gastrointestinal toxicity was 15%. Four patients relapsed with a five-year rate of 14% of recurrences. Conclusions: Adjuvant concomitant CR is well tolerated and is a feasible regimen in "high risk" patients. The authors' new algorithm treatment could be used for management and further clinical studies.

Keywords

Endometrial cancer; Radiotherapy; Adjuvant chemotherapy; Toxicity.

Cite and Share

D. Rossetti,S.G. Vitale,F.A. Gulino,P. Cignini,A.M.C. Rapisarda,A. Biondi,L. Frigerio. Concomitant chemoradiation treatment in selected Stage I endometrioid endometrial cancers. European Journal of Gynaecological Oncology. 2016. 37(5);657-661.

References

[1] Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., Vergote I.: “Endometrial cancer”. Lancet, 2005, 366, 491.

[2] Maggino T., Romagnolo C., Landoni F., Sartori E., Zola P., Gadducci A.: “An analysis of approaches to the management of endometrial cancer in North America: a CTF study”. Gynecol. Oncol., 1998, 68, 274.

[3] Creutzberg C.L., van Putten W.L., Wárlám-Rodenhuis C.C., van den Bergh A.C., de Winter K.A., Koper P.C., et al.: “Postoperative radiation therapy in endometrial carcinoma trial. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial”. J. Clin. Oncol., 2004, 22, 1234.

[4] Laufer J., Scasso S., Papadia A., Sosa C., Cirillo F., Raspagliesi F.: “Association between tumor diameter and lymphovascular space invasion among women with early-stage endometrial cancer”. Int. J. Gynaecol. Obstet., 2013, 123, 142-5.

[5] Fanning J., Tsukada Y., Piver M.S.: “Intraoperative frozen section diagnosis of depth of myometrial invasion in endometrial adenocarcinoma”. Gynecol. Oncol., 1990, 37, 47.

[6] Creasman W.T., Odicino F., Maisonneuve P., Quinn M.A., Beller U., Benedet J.L., et al.: “Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer”. Int. J. Gynaecol. Obstet., 2006, 95, S105.

[7] Thigpen J.T., Buchsbaum H.J., Mangan C., Blessing J.A.: “Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study”. Cancer Treat. Rep., 1979, 63, 21.

[8] Horton J., Begg C.B., Arseneault J., Bruckner H., Creech R., Hahn R.G.: “Comparison of Adriamycin with cyclophosphamide in patients with advance endometrial cancer”. Cancer Treat. Rep., 1978, 62, 159.

[9] Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., et al.: “Phase III trial of doxorubicin plus cisplatin with our without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study”. J. Clin. Oncol., 2004, 22, 2159.

[10] Thigpen J.T., Blessing J.A., Homesley H., Creasman W.T., Sutton G.: “Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study”. Gynecol. Oncol., 1989, 33, 68.

[11] Long H.J., Pfeifle D.M., Wieand H.S., Krook J.E., Edmonson J.H., Buckner J.C.: “Phase II evaluation of carboplatin in advanced endometrial carcinoma”. J. Natl. Cancer Inst., 1988, 80, 276.

[12] Frigerio L., Mangili G., Aletti G., Carnelli M., Garavaglia E., Beatrice S., Ferrari A.: “Concomitant radiotherapy and paclitaxel for high- risk endometrial cancer: first feasibility study”. Gynecol.Oncol., 2001, 81, 53.

[13] Mangili G., De Marzi P., Beatrice S., Rabaiotti E., Viganò R., Frigerio L., et al.: “Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings”. BMC Cancer, 2006, 6, 198.

[14] De Marzi P., Frigerio L., Cipriani S., Parazzini F., Busci L., Carlini L., et al.: “Adjuvant treatment with concomitant radiotherapy and chemotherapy in high-risk endometrial cancer: a clinical experience”.Gynecol. Oncol., 2010, 116, 408.

[15] Mangili G., De Marzi P., Viganò R., Rabaiotti E., Sassi I., Taccagni G.L., et al.: “Identification of high risk patients with endometrialcarcinoma. Prognostic assessment of endometrial cancer”. Eur. J. Gynaecol. Oncol., 2002, 23, 216.

[16] Nout R.A., Putter H., Jürgenliemk-Schulz I.M., Jobsen J.J., Lutgens L.C., van der Steen-Banasik E.M., et al.: “Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data”. Eur. J. Cancer, 2012, 48, 1638.

[17] Creutzberg C.L., Nout R.A., Lybeert M.L., Wárlám-Rodenhuis C.C., Jobsen J.J., Mens J.W., et al.: “PORTEC Study Group. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma”. Int. J. Radiat. Oncol. Biol. Phys., 2011, 81, e631.

[18] Greven K.M., Randall M., Fanning J., Bahktar M., Duray P., Peters A., Curran W.J. Jr.: “Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium”. Int. J. Radiat. Oncol. Biol. Phys., 1990, 19, 529.

[19] Sood B.M., Timmins P.F., Gorla G.R., Garg M., Anderson P.S., Vikram B., Goldberg G.L.: “Concomitant cisplatin and extended field radiation therapy in patients with cervical and endometrial cancer”. Int. J. Gynecol. Cancer, 2002, 12, 459.

[20] Morrow C.P., Bundy B.N., Homesley H.D., Creasman W.T., Hornback N.B., Kurman R., Thigpen J.T.: “Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study”. Gynecol. Oncol., 1990, 36, 166.

[21] Greven K., Winter K., Underhill K., Fontenesci J., Cooper J., Burke T.: “Final analysis of RT OG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer”. Gynecol.Oncol., 2006, 103, 155.

[22] Foad I., Sharawy I., Mostafa E., Margergis M., Hussein T.: “Concurrent cisplatin/radiation followed by adjuvant cisplatin/paclitaxel in treatment of patients with stage IB grade 3, IC and IIA endometrial carcinoma”. J. Egypt Natl. Cancer Inst., 2007, 19, 163.

[23] Alektiar K.M., Makker V., Abu-Rustum N.R., Soslow R.A., Chi D.S., Barakat R.R., Aghajanian C.A.: “Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I–II serous endometrial cancer”. Gynecol. Oncol., 2009, 112, 142.

[24] Bruzzone M., Miglietta L., Franzone P., Gadducci A., Boccardo F.: “Combined treatment with chemotherapy and radiotherapy in highrisk FIGO stage III–IV endometrial cancer patients”. Gynecol. Oncol., 2004, 93, 345.

[25] Kuoppala T., Mäenpää J., Tomas E., Puistola U., Salmi T., Grenman S., et al.: “Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemoradiotherapy”. Gynecol. Oncol., 2008, 110, 190.

[26] Gehrig P.A., Morris D.E., Van Le L.: “Uterine serous carcinoma: a comparison of therapy for advanced-stage disease”. Int. J. Gynecol. Cancer, 2004, 14, 515.

[27] Sehouli J., Koensgen D., Oskay-Ozcelik G., Mustea A.: “New aspects of adjuvant therapy in endometrial cancer: current standards and future directions”. Crit. Rev. Oncol. Hematol., 2008, 67, 204.

[28] Tewari K.S., Filiaci V.L., Spirtos N.M., Mannel R.S., Thigpen J.T., Cibull M.L., et al.: “Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2012, 125, 87.

[29] Lupe K., Kwon J., D'Souza D., Gawlik C., Stitt L., Whiston F., et al.: “Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach”. Int. J. Radiat. Oncol. Biol. Phys., 2007, 67, 110.

[30] Sorbe B., Andersson H., Boman K., Rosenberg P., Kalling M.: “Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up”. Int. J. Gynecol. Cancer, 2008, 18, 803.

[31] Pectasides D., Xiros N., Papaxoinis G., Pectasides E., Sykiotis C., Koumarianou A., et al.: ”Carboplatin and paclitaxel in advanced or metastatic endometrial cancer”. Gynecol. Oncol., 2008, 109, 250.

[32] Mariani A., Sebo T.J., Katzmann J.A., Keeney G.L., Roche P.C., Lesnick T.G., Podratz K.C.: ”Pretreatment assessment of prognostic indicators in endometrial cancer”. Am. J. Obstet. Gynecol., 2000, 182, 1535.

[33] Vaizoglu F., Yuce K., Salman M.C., Basaran D., Calis P., Ozgul N., Usubutun A.: “Lymphovascular space involvement is the sole independent predictor of lymph node metastasis in clinical early stage endometrial cancer”. Arch. Gynecol. Obstet., 2013, 288, 1391.

[34] Chattopadhyay S., Cross P., Nayar A., Galaal K., Naik R.: “Tumorsize: a better independent predictor of distant failure and death than depth of myometrial invasion in International Federation of Gynecology and Obstetrics stage I endometrioid endometrial cancer”. Int. J. Gynecol. Cancer, 2013, 23, 690.

[35] Susini T., Amunni G., Molino C., Carriero C., Rapi S., Branconi F., et al.: “Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: DNA aneuploidy identifies high-risk cases among the so-called ‘low-risk’ patients with well and moderately differentiated tumors”. Cancer, 2007, 109, 882.

[36] Zaino R.J., Davis A.T., Ohlsson-Wilhelm B.M., Brunetto V.L.: “DNA content is an independent prognostic indicator in endometrial adenocarcinoma. A Gynecologic Oncology Group study”. Int. J. Gynecol. Pathol., 1998, 17, 312.

[37] Mariani A., Webb M.J., Keeney G.L., Lesnick T.G., Podratz K.C.: “Surgical stage I endometrial cancer: predictors of distant failure and death”. Gynecol. Oncol., 2002, 87, 274.

[38] AlHilli M.M., Podratz K.C., Dowdy S.C., Bakkum-Gamez J.N., Weaver A.L., McGree M.E., et al.: “Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer”. Gynecol. Oncol., 2013, 128, 294.

[39] Briët J.M., Hollema H., Reesink N., Aalders J.G., Mourits M.J., ten Hoor K.A., et al.: “Lymphvascular space involvement: an independent prognostic factor in endometrial cancer”. Gynecol. Oncol., 2005, 96, 799.

[40] Simpkins F., Papadia A., Kunos C., Michener C., Frasure H., AbuShahin F., et al.: “Patterns of recurrence in stage I endometrioid endometrial adenocarcinomawith lymphovascular space invasion”. Int. J. Gynecol. Cancer, 2013, 23, 98.

[41] Jongen V.H., Briët J.M., de Jong R.A., Joppe E., ten Hoor K.A., Boezen H.M., et al.: “Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer”. Int. J. Gynecol. Cancer, 2009, 19, 670.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top